Central South University | China
Publication Profile
🎓 Early Academic Pursuits
Dr. Yiying Yang began her academic journey at Central South University, one of China’s leading institutions in medical research and education. With a strong foundation in basic medical sciences, she pursued advanced training in Pathophysiology at the School of Basic Medicine Science, and further honed her scientific acumen through postdoctoral research in Biology, also at Central South University. Her early academic trajectory reflects a deep commitment to understanding disease mechanisms at the molecular and cellular level.
🧪 Professional Endeavors
Dr. Yang is currently affiliated with Xiangya Hospital, a top-tier teaching hospital of Central South University, where she serves in the Department of Rheumatology. She also holds roles in the Sepsis Translational Medicine Key Lab of Hunan Province, and has contributed to national research platforms such as the Provincial Clinical Research Center for Rheumatic and Immunologic Diseases and the National Clinical Research Center for Geriatric Disorders. Her multidisciplinary affiliations underline her versatile expertise and leadership in translational medicine and clinical research.
🔬 Contributions and Research Focus
A prominent theme in Dr. Yang’s research is the identification of novel biomarkers in autoimmune and inflammatory diseases. Her most recent work, titled “Uncovering NINJ1 in SLE: Biomarker Potential for Renal and Hematologic Manifestations”, published in Clinica Chimica Acta, sheds light on the potential of NINJ1, a nerve injury-induced protein, as a diagnostic and stratification biomarker in Systemic Lupus Erythematosus (SLE). The study demonstrated that serum NINJ1 levels were significantly elevated in SLE patients, especially those with lupus nephritis and thrombocytopenia, correlating strongly with proteinuria, CRP, and NLR—markers of inflammation and disease severity.
🌍 Impact and Influence
Dr. Yang’s research not only enhances diagnostic accuracy but also offers promise for personalized treatment strategies in autoimmune diseases. Her work bridges clinical practice and molecular science, providing insights into immune dysregulation in SLE and contributing to global efforts in autoimmune disease management. Her findings could guide future therapeutic targets by implicating NINJ1 in the disease pathway, potentially transforming how SLE is monitored and treated.
📚 Academic Citations and Recognition
The publication, cited as:
Li M., Liu K., Liu M., Zhang H., Yang Y. (2025). Uncovering NINJ1 in SLE: Biomarker potential for renal and hematologic manifestations. Clinica Chimica Acta, https://doi.org/10.1016/j.cca.2025.120347
…has garnered attention in clinical immunology circles. This study is positioned to be widely cited upon its final release due to its innovative approach and robust statistical validation (AUC = 0.83 in ROC analysis).
🖥️ Technical Skills
Dr. Yang employs a range of technical methodologies including ELISA-based serum assays, clinical parameter analysis, and Receiver Operating Characteristic (ROC) curve evaluations. Her ability to synthesize clinical data with experimental science reflects her strong command over biostatistics, clinical diagnostics, and autoimmune disease modeling.
👩🏫 Teaching and Mentoring Experience
In addition to her research activities, Dr. Yang is involved in postgraduate mentorship and medical education at Central South University. As a mentor in the Postdoctoral Research Station of Biology, she plays a vital role in guiding emerging scientists, integrating classroom teaching with laboratory-based learning, and promoting evidence-based research training.
🌱 Legacy and Future Contributions
Dr. Yiying Yang is positioned to become a leading figure in autoimmune disease research in Asia and beyond. Her focus on translational biomarkers promises to bring clarity to complex disorders like SLE, where early detection and stratified treatment remain clinical priorities. Her contributions are laying the groundwork for next-generation diagnostics and personalized care pathways, reinforcing her role as a catalyst for medical innovation.
📚 Top Notes Publications
-
Title: EZH2 promotes B-cell autoimmunity in primary Sjogren’s syndrome via METTL3-mediated m6A modification
-
Authors: Yiying Yang, Muyuan Li, Liqing Ding, Ying Zhang, Ke Liu, Meidong Liu, Yisha Li, Hui Luo, Xiaoxia Zuo, Huali Zhang et al.
-
Journal: Journal of Autoimmunity
-
Year: 2024
-
Title: Negative regulator IL-1 receptor 2 (IL-1R2) and its roles in immune regulation of autoimmune diseases
-
Authors: Ying Zhang, Ke Liu, Muyao Guo, Yiying Yang, Huali Zhang
-
Journal: International Immunopharmacology
-
Year: 2024
-
Title: PANoptosis Features, a Humanized NSG Murine Model of Sjogren’s Syndrome
-
Authors: Yiying Yang, Huali Zhang, Xiaoyu Xiao, Muyao Guo
-
Journal: DNA and Cell Biology
-
Year: 2024
-
Title: Identification of EPSTI1 as a new potential biomarker for SLE based on GEO database
-
Authors: Yang Y, Zhang H, Xiao X, Muyao Guo
-
Journal: Clinical Rheumatology
-
Year: 2024
-
Title: Patients with dermatomyositis shared partially similar transcriptome signature with COVID-19 infection
-
Authors: Yang Y, Song J, Zhao H, Zhang H, Guo M
-
Journal: Autoimmunity
-
Year: 2023